Clearmind Medicine Inc. (CMND) - Dilution Analysis

POS AM filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to aggregate of 331,949 common shares, no par value, of Clearmind Medicine Inc. issuable upon the exercise of warrants, or the January 2024 PIPE Warrants, originally issued in a private placement on January 16, 2024.

POS AM filing: This prospectus relates to the resale of common shares issuable upon the exercise of warrants originally issued in a private placement.

POS AM filing: This prospectus relates to the resale of up to 1,126,480 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

POS AM filing: This is a POS AM filing for Clearmind Medicine Inc. relating to the resale of up to 1,126,480 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

POS AM filing: This prospectus relates to the resale of up to 1,126,480 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

20-F filing | 4.3M shares outstanding

POS AM filing: This POS AM filing relates to the resale of up to 1,331,480 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

POS AM filing: This is a POS AM filing for Clearmind Medicine Inc. relating to the resale of up to 1,331,480 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

POS AM filing: This POS AM filing relates to the resale of up to 1,500,000 common shares issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024.

F-1 filing: Registration of 1,500,000 common shares for resale by selling shareholders, issuable upon exercise of warrants from a private placement on January 16, 2024.

20-F filing | 0.6M shares outstanding

POS AM filing: This prospectus relates to the issuance of up to 1,047,384 Common Shares, upon the exercise of (i) warrants to purchase 483,461 Common Shares and (ii) warrants to purchase 563,923 Common Shares.

F-3 filing: Clearmind Medicine Inc. files an F-3 form to offer, issue and sell from time to time up to US $50,000,000 of our Common Shares, subscription rights, warrants, and a combination of such securities, separately or as units, in one or more offerings.

F-1 filing: Clearmind Medicine Inc. is offering up to $7.0 million of Common Shares, Pre-Funded Warrants, and Common Warrants on a reasonable best efforts basis. The offering consists of up to 15,217,391 Common Shares at an assumed price of $0.46 per share and includes Pre-Funded Warrants and Common Warrants to purchase additional Common Shares.

F-1 filing: Clearmind Medicine Inc. is offering up to $15 million of Common Shares, Pre-Funded Warrants, and Common Warrants on a reasonable best efforts basis.

20-F filing | 1.3M shares outstanding

F-1 filing: This is an F-1 filing for the initial public offering of Clearmind Medicine Inc., offering units consisting of common shares and warrants, with the intention to list on The Nasdaq Capital Market.